BR112017027332A2 - composições tópicas que compreendem um corticosteróide e um retinóide para tratar psoríase. - Google Patents

composições tópicas que compreendem um corticosteróide e um retinóide para tratar psoríase.

Info

Publication number
BR112017027332A2
BR112017027332A2 BR112017027332-2A BR112017027332A BR112017027332A2 BR 112017027332 A2 BR112017027332 A2 BR 112017027332A2 BR 112017027332 A BR112017027332 A BR 112017027332A BR 112017027332 A2 BR112017027332 A2 BR 112017027332A2
Authority
BR
Brazil
Prior art keywords
retinoid
corticosteroid
topical compositions
treating psoriasis
psoriasis
Prior art date
Application number
BR112017027332-2A
Other languages
English (en)
Other versions
BR112017027332B1 (pt
Inventor
J. Dow Gordon
Pillai Radhakrishnan
Bhatt Varsha
Original Assignee
Valeant Pharmaceuticals North America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56131662&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017027332(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valeant Pharmaceuticals North America filed Critical Valeant Pharmaceuticals North America
Publication of BR112017027332A2 publication Critical patent/BR112017027332A2/pt
Publication of BR112017027332B1 publication Critical patent/BR112017027332B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112017027332-2A 2015-06-18 2016-06-06 Composição farmacêutica tópica para tratar psoríase e seu uso BR112017027332B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562181481P 2015-06-18 2015-06-18
US62/181,481 2015-06-18
PCT/US2016/035991 WO2016205001A1 (en) 2015-06-18 2016-06-06 Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis

Publications (2)

Publication Number Publication Date
BR112017027332A2 true BR112017027332A2 (pt) 2018-09-04
BR112017027332B1 BR112017027332B1 (pt) 2023-11-07

Family

ID=56131662

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017027332-2A BR112017027332B1 (pt) 2015-06-18 2016-06-06 Composição farmacêutica tópica para tratar psoríase e seu uso

Country Status (20)

Country Link
US (7) US10251895B2 (pt)
EP (1) EP3310389B1 (pt)
JP (1) JP6997624B2 (pt)
KR (2) KR102643849B1 (pt)
CN (1) CN108282998B (pt)
AU (1) AU2016279801B2 (pt)
BR (1) BR112017027332B1 (pt)
CA (1) CA2988577A1 (pt)
CY (1) CY1123354T1 (pt)
DK (1) DK3310389T3 (pt)
ES (1) ES2812451T3 (pt)
HR (1) HRP20201250T1 (pt)
HU (1) HUE050603T2 (pt)
LT (1) LT3310389T (pt)
MX (1) MX2017015990A (pt)
PL (1) PL3310389T3 (pt)
PT (1) PT3310389T (pt)
RS (1) RS60672B1 (pt)
SI (1) SI3310389T1 (pt)
WO (1) WO2016205001A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
KR102643849B1 (ko) * 2015-06-18 2024-03-07 밸리언트 파마슈티컬즈 노오쓰 아메리카 엘엘씨 건선을 치료하기 위한 코르티코스테로이드 및 레티노이드를 포함하는 국소 조성물
CN108024954A (zh) * 2015-07-13 2018-05-11 瑞迪博士实验室有限公司 局部用类视黄醇组合物
BR112019023817A8 (pt) * 2017-05-12 2022-12-06 Bausch Health Us Llc Composições tópicas e métodos para o tratamento de doenças da pele
US11311482B2 (en) * 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
JP7065895B2 (ja) * 2017-06-23 2022-05-12 ラボラトリオス・サルバト・ソシエダッド・アノニマ クロベタゾールの水中油型ナノエマルジョン組成物
US10653656B2 (en) 2018-04-05 2020-05-19 Bausch Health Ireland Limited Topical pharmaceutical compositions for treating skin conditions
EP3775116A4 (en) * 2018-04-05 2022-03-23 Bausch Health Ireland Limited POLYMER EMULSION DISTRIBUTION SYSTEMS
US10945952B2 (en) 2019-03-14 2021-03-16 Crescita Therapeutics Inc. Rinse-off compositions and uses thereof for delivery of active agents
KR102327827B1 (ko) 2019-11-01 2021-11-18 한국과학기술연구원 강황 추출물을 유효성분으로 포함하고 자외선 처리를 포함하는 건선 개선용 조성물
CN113116891B (zh) * 2019-12-30 2024-07-16 重庆华邦制药有限公司 一种乳膏及其制备方法
KR102527907B1 (ko) 2020-09-14 2023-05-03 한국과학기술연구원 무산상자 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102451304B1 (ko) 2020-09-14 2022-10-07 한국과학기술연구원 꿩의다리속 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102461001B1 (ko) 2020-09-14 2022-11-01 한국과학기술연구원 술패랭이꽃 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR20230041257A (ko) 2021-09-17 2023-03-24 한국과학기술연구원 시미시푸고라이드 에이를 유효성분으로 포함하는 건선 개선용 조성물
KR20230041255A (ko) 2021-09-17 2023-03-24 한국과학기술연구원 눈개승마 추출물을 유효성분으로 포함하는 건선 개선용 조성물
CN113975249B (zh) * 2021-10-14 2023-01-03 中山大学·深圳 Tris-BNP纳米颗粒的制备及其在皮肤疾病治疗中的应用
CN113712918A (zh) * 2021-10-28 2021-11-30 济南纽华医药科技有限公司 一种阿普斯特微乳及其制备方法
WO2024141639A1 (en) * 2022-12-31 2024-07-04 Bausch Health Ireland Limited Use of a fixed combination of halobetasol propionate and tazarotene to treat conditions mediated by interleukin-17a

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU75903A1 (pt) 1976-09-29 1978-05-16
NL7105591A (en) 1971-04-24 1972-10-26 Topical antiphlogistic compsns - contng 3, 20-diketo-9 alpha, 11 beta-dichloro - 16 alpha, 17 alpha-dimethyl-21-hydroxy pregna-1,4-
DE2655570A1 (de) 1975-12-12 1977-06-16 Ciba Geigy Ag Neue polyhalogensteroide und verfahren zu ihrer herstellung
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
US4083974A (en) 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
JPS5850964B2 (ja) 1978-03-07 1983-11-14 東興薬品工業株式会社 ステロイド含有クリ−ム製剤およびその製造方法
US4299828A (en) 1979-05-31 1981-11-10 E. R. Squibb & Sons, Inc. Corticosteroid stick formulations
AU5794680A (en) 1979-05-31 1980-12-04 E.R. Squibb & Sons, Inc. Corticosteroid stick formulations
US4233295A (en) 1979-05-31 1980-11-11 E. R. Squibb & Sons, Inc. Corticosteroid formulations containing sebacate carrier
CH649923A5 (de) 1980-10-06 1985-06-28 Glaxo Group Ltd Topisch verabreichbare pharmazeutische zusammensetzungen, enthaltend anti-inflammatorische steroide.
JPS58225009A (ja) 1982-06-23 1983-12-27 Shionogi & Co Ltd コルチコステロイド外用製剤
DE3225848A1 (de) 1982-07-07 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Kortikoidhaltige zubereitung zur topischen applikation
GB8401965D0 (en) 1984-01-25 1984-02-29 Beecham Group Plc Composition
CA1303991C (en) 1986-03-31 1992-06-23 Chung H. Cheng Composition and method for delivering a steroid active ingredient
US5019569A (en) 1986-11-03 1991-05-28 Ortho Pharmaceutical Corporation Reversal of glucocorticoid-induced skin atrophy
JPH0676327B2 (ja) 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイド軟膏製剤
JPH0676328B2 (ja) 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイドクリ−ム製剤
JPH07116026B2 (ja) 1987-07-07 1995-12-13 株式会社資生堂 ジクロフェナックナトリウム含有乳化外用剤
US5422361A (en) 1989-12-20 1995-06-06 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
JP3340126B2 (ja) 1990-03-02 2002-11-05 株式会社資生堂 非ステロイド系消炎鎮痛薬を含む水中油型乳化組成物
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
TW218849B (pt) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
EP0969847A1 (en) 1997-02-20 2000-01-12 Allergan Sales, Inc. Tazarotene and corticosteroid treatment for psoriasis
SE9800729L (sv) 1998-03-06 1999-09-07 Scotia Lipidteknik Ab Ny topikal formulering I
GB9823036D0 (en) 1998-10-22 1998-12-16 Glaxo Group Ltd Fluticasone lotion having improved vasoconstrictor activity
AU2877800A (en) * 1999-02-12 2000-08-29 Susan Bershad Short contact treatment of psoriasis with topical retinoids
US6730308B1 (en) * 1999-03-08 2004-05-04 Allergan, Inc. Tazarotene and alpha hydroxy acid treatment for psoriasis and/or photodamage
US6656928B1 (en) 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
US6479058B1 (en) 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
MXPA03003511A (es) * 2000-10-27 2004-05-04 Leo Pharma As Composicion topica que contiene al menos una vitamina d o un analogo de vitamina de y al menos un corticosteroide.
US6709663B2 (en) 2001-08-31 2004-03-23 Healthpoint, Ltd. Multivesicular emulsion drug delivery systems
US6765001B2 (en) 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US7544674B2 (en) 2002-10-25 2009-06-09 Galderma S.A. Topical skin care composition
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
CN1210034C (zh) * 2002-12-06 2005-07-13 重庆华邦制药股份有限公司 治疗银屑病的药物组合物
AU2003302305A1 (en) 2002-12-31 2004-07-22 Sachin S Bhagwat Benzoquinolizine-2-carboxylic acid-containing compositions
JP2004359585A (ja) 2003-06-03 2004-12-24 Medorekkusu:Kk 被膜形成型の副腎皮質ステロイド薬含有外用製剤
CN1210041C (zh) * 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗痤疮的复方外用药物
CN1210035C (zh) * 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗银屑病的复方外用药物
US8741333B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
JPWO2006098353A1 (ja) 2005-03-15 2008-08-28 協和醗酵工業株式会社 外用剤
TW200740441A (en) 2005-06-17 2007-11-01 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
JP2009519956A (ja) 2005-12-14 2009-05-21 ザーズ， インコーポレイテッド 薬物の皮膚送達のための組成物および方法
WO2008038147A2 (en) 2006-07-05 2008-04-03 Foamix Ltd. Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof
WO2008152444A2 (en) 2006-11-29 2008-12-18 Foamix Ltd. Foamable waterless compositions with modulating agents
WO2009063493A2 (en) 2007-09-10 2009-05-22 Glenmark Pharmaceuticals Limited Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid
WO2009084020A2 (en) 2007-10-18 2009-07-09 Glenmark Pharmaceuticals Limited Topical composition comprising halobetasol and salicylic acid
KR102080429B1 (ko) 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
JP6130992B2 (ja) 2009-02-25 2017-05-17 スティーフェル リサーチ オーストラリア ピーティーワイ リミテッド 局所用フォーム組成物
US20130310355A1 (en) 2009-12-15 2013-11-21 Young Pharmaceuticals, Inc. Low toxicity topical active agent delivery system
US9782341B2 (en) 2010-10-15 2017-10-10 John E. Kulesza Delivery of hydrophobic bioactive agents
CN107308163A (zh) * 2010-11-04 2017-11-03 442合资有限责任公司 用于治疗皮肤病的组合物和方法
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US9034926B2 (en) * 2010-12-30 2015-05-19 Nicholas V. Perricone Topical nitrone spin trap compositions for psoriasis
WO2012167018A1 (en) 2011-06-03 2012-12-06 Allergan, Inc. Targeted delivery of retinoid compounds to the sebaceous glands
SG11201403762PA (en) 2012-01-09 2014-07-30 Almirall Sa Topical pharmaceutical compositions comprising bexarotene and a corticosteroids
US20140112959A1 (en) 2012-10-18 2014-04-24 MiCal Pharmaceuticals LLC - H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limite Topical steroid composition and method
CN104288157B (zh) * 2013-01-29 2018-04-13 江苏知原药业有限公司 包含丙酸氯倍他索和维a酸的固体分散体及其制备方法
WO2015044857A1 (en) * 2013-09-25 2015-04-02 Ranbaxy Laboratories Limited Topical spray composition of halobetasol
KR102643849B1 (ko) 2015-06-18 2024-03-07 밸리언트 파마슈티컬즈 노오쓰 아메리카 엘엘씨 건선을 치료하기 위한 코르티코스테로이드 및 레티노이드를 포함하는 국소 조성물
US20190133943A1 (en) 2015-06-18 2019-05-09 Valeant Pharmaceuticals North America Topical compositions and methods for treating skin diseases
BR112019023817A8 (pt) 2017-05-12 2022-12-06 Bausch Health Us Llc Composições tópicas e métodos para o tratamento de doenças da pele
US11311482B2 (en) * 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases

Also Published As

Publication number Publication date
MX2017015990A (es) 2018-11-09
CY1123354T1 (el) 2021-12-31
US20190231797A1 (en) 2019-08-01
US20210330681A1 (en) 2021-10-28
HRP20201250T1 (hr) 2020-11-13
EP3310389B1 (en) 2020-07-01
KR102643849B1 (ko) 2024-03-07
AU2016279801A1 (en) 2018-01-04
US20180177803A1 (en) 2018-06-28
DK3310389T3 (da) 2020-08-10
AU2016279801B2 (en) 2021-09-09
ES2812451T3 (es) 2021-03-17
WO2016205001A1 (en) 2016-12-22
HUE050603T2 (hu) 2020-12-28
US20160367570A1 (en) 2016-12-22
PL3310389T3 (pl) 2020-11-30
CN108282998B (zh) 2021-07-06
JP2018526325A (ja) 2018-09-13
US11648256B2 (en) 2023-05-16
BR112017027332B1 (pt) 2023-11-07
US10426787B2 (en) 2019-10-01
US11679116B2 (en) 2023-06-20
US10251895B2 (en) 2019-04-09
US20230086282A1 (en) 2023-03-23
JP6997624B2 (ja) 2022-01-17
LT3310389T (lt) 2020-11-10
EP3310389A1 (en) 2018-04-25
SI3310389T1 (sl) 2020-11-30
KR20180053292A (ko) 2018-05-21
RS60672B1 (sr) 2020-09-30
US20230355640A1 (en) 2023-11-09
CA2988577A1 (en) 2016-12-22
PT3310389T (pt) 2020-11-11
US11679115B2 (en) 2023-06-20
CN108282998A (zh) 2018-07-13
US20210145847A1 (en) 2021-05-20
KR20240035898A (ko) 2024-03-18

Similar Documents

Publication Publication Date Title
BR112017027332A2 (pt) composições tópicas que compreendem um corticosteróide e um retinóide para tratar psoríase.
DK3258942T3 (da) Kosmetiske og topiske sammensætninger omfattende cannabigerol og cannabidiol
BR112018001190A2 (pt) composições úteis para tratar distúrbios relacionados a kit e pdfgr
ZA201800080B (en) Topical retinoid compositions
DK3307739T3 (da) NRF2-regulatorer
BR112017013320A2 (pt) composições inibidoras de corrosão para tratamentos de acidificação
CL2018003443A1 (es) Tratamientos para el cancer.
BR112017019352A2 (pt) composições tópicas comprimidas a corticosteróide aplicações relacionadas
CL2019001760A1 (es) Composiciones que comprenden ácido acético y ácido hipoclórico y métodos para tratar una biopelícula.
BR112018002283A2 (pt) Composição para administração tópica a um sujeito, e, formulação tópica
BR112015023273A2 (pt) método para programar a ovulação.
BR112016021875A2 (pt) composição tópica
DK3349752T3 (da) Aza-adamantan sammensætning til sårheling
DK3324938T3 (da) Topikale formuleringer og behandlinger
IL246800A0 (en) Local antifungal preparation for the treatment of nail fungus
BR112017016048A2 (pt) método e agente anti-inflamatório
ES1135628Y (es) Monoboya para vertido controlado
CL2018000985A1 (es) Composición y método para tratar sustratos.
CL2017002884A1 (es) Tratamientos para el cancer
MA42111A (fr) Compositions pharmaceutiques topiques
ES1166908Y (es) Apósito para pomada
ES1173908Y (es) Estructura para cinta de correr
ES1149333Y (es) Fondo para expositores de joyeria
TH1501004914A (th) องค์ประกอบทางผิวหนังวิทยาต้านจุลชีพแบบทา
ES1135740Y (es) Freno para tornillos de apriete

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15V Prolongation of time limit allowed

Free format text: DE ACORDO COM COMUNICADO PUBLICADO NA RPI 2526 DE 04/06/2019 FICAM DEVOLVIDOS DE 11/06/2019 ATE 14/06/2019 OS PRAZOS VENCIDOS NAS DATAS DIVULGADAS DENTRO DO COMUNICADO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/06/2016, OBSERVADAS AS CONDICOES LEGAIS